Gamida Cell Ltd.

Gamida Cell Ltd. is a biotechnology and healthcare company based in the United States. The company's slogan, "Working to turn cells into powerful therapeutics for patients with cancer," reflects its mission to revolutionize cell therapy for cancer treatment. Founded in 1998, Gamida Cell is a pioneer in the field, leveraging its proprietary nicotinamide (NAM) technology to expand the number of cells while maintaining their intrinsic properties, thereby creating potentially curative cell therapy products and candidates. One of their significant achievements includes the approval of their stem cell transplant therapy by the US FDA in April 2023, indicating a major breakthrough in the field of cell therapy. Additionally, the company's ongoing clinical study of their NK cell therapy candidate GDA-201 shows the company's commitment to advancing innovative treatment options for cancer patients. In terms of funding, Gamida Cell recently secured a $25.00M post-IPO debt investment on 28 September 2022, with Highbridge Capital Management as the investor. This funding is a testament to the confidence of investors in the company's potential and its ability to make a significant impact in the biotechnology and healthcare industries. Overall, Gamida Cell's innovative approach to cell therapy, coupled with its recent funding success and FDA approval, positions the company as a key player in the development of advanced cancer therapeutics, offering promising opportunities for both patients and investors.